|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
However, the precise role of JMJD6 in breast cancer development remains unclear.
|
30185813 |
2019 |
|
Malignant neoplasm of breast
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
We show that overexpression of JMJD6 increased HOTAIR expression and JMJD6 siRNAs suppressed it in ER+ MCF-7, triple negative MDA-MB-231 and non-breast cancer HEK 293 cells.
|
29229759 |
2018 |
|
Malignant neoplasm of breast
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Consistent with its role in transcriptional activation, JMJD6 is required for estrogen/ERα-induced breast cancer cell growth and tumorigenesis.
|
29628309 |
2018 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry, siRNA-mediated silencing, and forced overexpression of JMJD6 in cell-based assays elucidated molecular mechanisms of JMJD6 action in breast cancer progression and shed light on the clinical breast cancer subtypes relevant to JMJD6 action.
|
22621393 |
2012 |
|
Malignant neoplasm of breast
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Although JMJD6 displays anti-tumoral properties in cell lines, its expression in breast tumours may be a marker of poor prognosis, suggesting that its function could be altered in breast cancer.
|
25951181 |
2015 |
|
Breast Carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Although JMJD6 displays anti-tumoral properties in cell lines, its expression in breast tumours may be a marker of poor prognosis, suggesting that its function could be altered in breast cancer.
|
25951181 |
2015 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry, siRNA-mediated silencing, and forced overexpression of JMJD6 in cell-based assays elucidated molecular mechanisms of JMJD6 action in breast cancer progression and shed light on the clinical breast cancer subtypes relevant to JMJD6 action.
|
22621393 |
2012 |
|
Breast Carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Consistent with its role in transcriptional activation, JMJD6 is required for estrogen/ERα-induced breast cancer cell growth and tumorigenesis.
|
29628309 |
2018 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
However, the precise role of JMJD6 in breast cancer development remains unclear.
|
30185813 |
2019 |
|
Breast Carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
We show that overexpression of JMJD6 increased HOTAIR expression and JMJD6 siRNAs suppressed it in ER+ MCF-7, triple negative MDA-MB-231 and non-breast cancer HEK 293 cells.
|
29229759 |
2018 |
|
melanoma
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
We found that high expression of JMJD6 is closely correlated with advanced clinicopathologic stage, aggressiveness, and poor prognosis of melanoma.
|
29187213 |
2017 |
|
melanoma
|
0.320 |
Biomarker
|
disease |
BEFREE |
Indeed, triple transgenic fish engineered to express a microRNA-resistant Jmjd6 from the onset of melanoma have increased tumor burden, higher infiltration of leukocytes and shorter melanoma-free survival.
|
30619488 |
2018 |
|
Mammary Neoplasms
|
0.320 |
AlteredExpression
|
group |
BEFREE |
We propose that high JMJD6 expression may achieve higher levels of HOTAIR in breast tumors.
|
29229759 |
2018 |
|
Mammary Neoplasms
|
0.320 |
AlteredExpression
|
group |
BEFREE |
The analysis of JMJD6 expression in a cohort of breast tumour samples indicates that JMJD6 was highly expressed in aggressive breast tumours.
|
25951181 |
2015 |
|
Uveal melanoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
KRas-ERK signalling promotes the onset and maintenance of uveal melanoma through regulating JMJD6-mediated H2A.X phosphorylation at tyrosine 39.
|
31736361 |
2019 |
|
ovarian neoplasm
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we found that the high expression of JMJD6 in ovarian cancer was correlated with poor prognosis in ovarian cancer.
|
31637004 |
2019 |
|
Malignant neoplasm of ovary
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we found that the high expression of JMJD6 in ovarian cancer was correlated with poor prognosis in ovarian cancer.
|
31637004 |
2019 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Indeed, triple transgenic fish engineered to express a microRNA-resistant Jmjd6 from the onset of melanoma have increased tumor burden, higher infiltration of leukocytes and shorter melanoma-free survival.
|
30619488 |
2018 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
We first showed that miR-770 was downregulated in NSCLC tissues and cell lines, and the low expression of miR-770 was correlated with poor patient survival in NSCLC patients. miR-770 acted on a tumor suppressor by binding to the 3'UTR of JMJD6 and downregulated its expression in NSCLC cells.
|
28882645 |
2017 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Combination therapy with the CDK7/super-enhancer inhibitor THZ1 and the histone deacetylase inhibitor panobinostat synergistically reduces JMJD6, E2F2, N-Myc, c-Myc expression, induces apoptosis in vitro and leads to neuroblastoma tumor regression in mice, which are significantly reversed by forced JMJD6 over-expression.
|
31346162 |
2019 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
JMJD6 was expressed at highest levels in tumors associated with worse outcomes, including ER- and basal-like, Claudin-low, Her2-enriched, and ER+ Luminal B tumors.
|
22621393 |
2012 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
JMJD6 overexpression in MMTV-Myc cell lines increases tumor burden, induces EMT, and greatly enhances tumor metastasis.
|
27081402 |
2016 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical staining revealed that high JMJD6 expression was closely correlated with tumor size (P = 0.005), pathological grade (P = 0.003), pT status (P = 0.012), pN status (P = 0.003), and pleural invasion (P < 0.001).
|
23595221 |
2013 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
JMJD6 silencing in breast tumoural cells promotes certain characteristics of tumourigenesis including proliferation, migration in vitro, and tumour growth in vivo.
|
25951181 |
2015 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
In tumor samples but not normal breast tissue, the expression of JMJD6 linearly correlated with HOTAIR suggesting that JMJD6-mediated up-regulation may occur specifically in tumors.
|
29229759 |
2018 |